Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Journal
Liver Cancer
Journal Volume
8
Journal Issue
6
Pages
480-490
Date Issued
2019
Author(s)
Chao Y.
Yen C.-J.
Hung Y.-P.
Chang C.-J.
Abstract
BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICIs) exhibit significant clinical activity in patients with advanced hepatocellular carcinoma (HCC). This study explored whether tumor response to ICIs in HCC varies among different organs. METHODS: We reviewed the data of patients with advanced HCC who had received ICIs. Patients with measurable diseases were enrolled. Organ-specific response criteria, adapted from RECIST 1.1 and immune-related RECIST, were used to evaluate the objective response to ICIs in tumors located in the liver, lung, lymph node, and other intra-abdominal sites. RESULTS: = 0.005). CONCLUSIONS: The hepatic tumors of HCC may be less responsive to ICIs than extrahepatic lesions. Lung metastases responded most favorably to ICIs. The mechanisms underlying this differential response to ICIs warrant further investigation.
SDGs
Publisher
S. Karger AG
Type
journal article